PL2448945T3 - Krystaliczne postacie soli prasugrelu - Google Patents

Krystaliczne postacie soli prasugrelu

Info

Publication number
PL2448945T3
PL2448945T3 PL11715144T PL11715144T PL2448945T3 PL 2448945 T3 PL2448945 T3 PL 2448945T3 PL 11715144 T PL11715144 T PL 11715144T PL 11715144 T PL11715144 T PL 11715144T PL 2448945 T3 PL2448945 T3 PL 2448945T3
Authority
PL
Poland
Prior art keywords
crystalline forms
prasugrel
salts
prasugrel salts
crystalline
Prior art date
Application number
PL11715144T
Other languages
English (en)
Inventor
Mihaela Tuksar
Tomislav Biljan
Miroslav Zegarac
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44065677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2448945(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL2448945T3 publication Critical patent/PL2448945T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL11715144T 2010-04-08 2011-04-07 Krystaliczne postacie soli prasugrelu PL2448945T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32216510P 2010-04-08 2010-04-08
US32688210P 2010-04-22 2010-04-22
US34891410P 2010-05-27 2010-05-27
US35530410P 2010-06-16 2010-06-16
EP11715144.9A EP2448945B1 (en) 2010-04-08 2011-04-07 Crystalline forms of prasugrel salts
PCT/US2011/031602 WO2011127300A1 (en) 2010-04-08 2011-04-07 Crystalline forms of prasugrel salts

Publications (1)

Publication Number Publication Date
PL2448945T3 true PL2448945T3 (pl) 2015-06-30

Family

ID=44065677

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11715144T PL2448945T3 (pl) 2010-04-08 2011-04-07 Krystaliczne postacie soli prasugrelu

Country Status (11)

Country Link
US (2) US8802854B2 (pl)
EP (2) EP2883877A1 (pl)
JP (2) JP5730986B2 (pl)
KR (3) KR20120052381A (pl)
CN (1) CN102656175B (pl)
ES (1) ES2533681T3 (pl)
HR (1) HRP20150356T1 (pl)
PL (1) PL2448945T3 (pl)
PT (1) PT2448945E (pl)
SI (1) SI2448945T1 (pl)
WO (1) WO2011127300A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2448945E (pt) * 2010-04-08 2015-04-09 Teva Pharma Formas cristalinas de sais de prasugrel
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
CN103173432B (zh) 2011-12-22 2020-08-04 通用电气公司 分离核酸的方法及装置
CN103012427B (zh) * 2012-11-26 2015-07-08 天津大学 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法
EP3106151A1 (en) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107814810A (zh) * 2016-09-14 2018-03-20 天津科技大学 一种普拉格雷硫酸氢盐新晶型及其制备方法
CN107915743A (zh) * 2016-10-10 2018-04-17 天津科技大学 一种普拉格雷硫酸氢盐晶型iv及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR20080021152A (ko) 2000-07-06 2008-03-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
TWI392681B (zh) 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
EP2436381A1 (en) 2006-06-27 2012-04-04 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
US20100261908A1 (en) 2007-11-09 2010-10-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel , and its salts and polymorphs
WO2009066326A2 (en) 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2009098142A1 (en) 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
CN101255169B (zh) 2008-03-26 2010-11-10 山东大学 普拉格雷盐及其制备方法
WO2009129983A1 (en) 2008-04-21 2009-10-29 Ratiopharm Gmbh Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
DE602008002820D1 (de) 2008-04-25 2010-11-11 Sandoz Ag Hydrogensulfat von 2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜpyridin und dessen Zubereitung
EP2325187A4 (en) 2008-08-02 2011-09-28 Lunan Pharm Group Corp PRASUGREL HYDROGENOSULFATE, ITS MEDICINAL COMPOUND AND USE THEREOF
WO2010070677A2 (en) 2008-12-15 2010-06-24 Glenmark Generics Limited A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2010094471A1 (en) 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
CN102365288B (zh) 2009-03-31 2014-04-09 上海医药工业研究院 普拉格雷氢溴酸盐的晶体
GB2469883A (en) 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
EP2451816A4 (en) * 2009-07-06 2013-02-27 Glenmark Generics Ltd CRYSTALLINE FORM OF PRASUGREL HYDROBROMIDE AND PROCESS FOR PREPARING THE SAME
CZ2009763A3 (cs) * 2009-11-16 2011-05-25 Zentiva, K. S. Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a jeho nových farmaceuticky prijatelných solí.
CZ2009762A3 (cs) * 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
PT2448945E (pt) * 2010-04-08 2015-04-09 Teva Pharma Formas cristalinas de sais de prasugrel
CN101899056A (zh) 2010-08-02 2010-12-01 江苏万全特创医药生物技术有限公司 普拉格雷氢溴酸盐多晶型物及其制备方法
CN101919823A (zh) * 2010-08-02 2010-12-22 北京德众万全医药科技有限公司 一种治疗血栓的药用组合物

Also Published As

Publication number Publication date
EP2448945B1 (en) 2015-01-07
PT2448945E (pt) 2015-04-09
EP2448945A1 (en) 2012-05-09
JP5730986B2 (ja) 2015-06-10
EP2883877A1 (en) 2015-06-17
US20140336217A1 (en) 2014-11-13
WO2011127300A1 (en) 2011-10-13
US20130085154A1 (en) 2013-04-04
KR101785186B1 (ko) 2017-10-12
US9012641B2 (en) 2015-04-21
KR20140110096A (ko) 2014-09-16
KR20150140871A (ko) 2015-12-16
JP2013523837A (ja) 2013-06-17
HRP20150356T1 (hr) 2015-05-08
CN102656175A (zh) 2012-09-05
US8802854B2 (en) 2014-08-12
ES2533681T3 (es) 2015-04-14
SI2448945T1 (sl) 2015-05-29
CN102656175B (zh) 2015-08-26
KR20120052381A (ko) 2012-05-23
JP2015096553A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
ZA201303586B (en) Salts and crystalline forms of an apoptosis-inducing agent
SG10201500451TA (en) Crystalline forms of a purine derivative
HUE047354T2 (hu) Ivacaftor deuterizált származékai
PL3235812T3 (pl) Deuterowane pochodne iwakaftoru
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
IL215315A0 (en) Solid state forms of sitagliptin salts
IL230976A0 (en) Crystalline forms of cvezitaxel
ZA201308160B (en) Crystalline salts of asenapine
SI2448945T1 (sl) Kristalinične oblike prasugrelovih soli
IL234401A (en) Crystalline structures of sitglyphatin sulfate
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
EP2760853A4 (en) NEW SALTS OF ALOGLIPTIN
PT2621496E (pt) Conjugado naloxol-peg cristalino
PT2571355T (pt) Sal de cloridrato cristalino de darunavir
EP2601178A4 (en) SALTS OF LAPATINIB
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
EP2601200A4 (en) PREPARATION FROM PRASUGRELHYDROCHLORIDE
ZA201406238B (en) Crystalline form of a succinate salt
IL223584A0 (en) Crystalline form of a 3-phenoxymethylpyrrolidine compounds
IL230977A (en) A crystalline form of relapaldib
PL2714707T3 (pl) Krystalizacja chlorowodorku epirubicyny
EP2616463A4 (en) PREPARATION OF CRYSTALLINE BAZEDOXIFES AND THEIR SALTS
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
ZA201209647B (en) Crystalline forms of kinase inhibitors